The SPORE Tissue Procurement and Analysis Facility (TPA) provides centralized, quality controlled, quality assured procurement, processing, analysis, storage and distribution of normal and malignant breast tissue from UNC Hospitals. Whenever possible, corresponding serum and plasma are also obtained. All procured specimens are reviewed by the Facility Pathologist to ensure that representative tissue is banked and distributed. Our tissue procurement activities have expanded to include Rex Hospital, a large Hospital in Raleigh, N.C., new to the UNC Health Care System, dramatically increasing our access to breast specimens. The TPA facility procures and distributes human specimens from patients who have consented to having their specimens used in basic, translational, population and clinical cancer research. The facility also provides analysis services, including tissue sectioning for frozen and paraffin embedded specimens, preparation of tissue microarrays (TMAs), immunohistochemistry and fluorescence in situ assays, technology development and access to state-of-the-art tissue-based technology, including automated equipment and laser-capture microdissection. Expert personnel provide consultation and training to faculty and staff in these applications. The facility also serves as a central clearing house for the Carolina Breast Cancer Study - banking anddistributing unstained sections for multiple assays andcentralized repository for the InterSPORE ISPY trial (Intergroup Neoadjuvant study: SPORE/CALGB/ ACRIN). Customized databases serve to monitor and survey all specimens and associated data, providing a coordinated system of quality control, sample tracking and distribution of specimens to appropriate investigators. The TPA has implemented policies and procedures to support these services and address technical, medical and legal issues, as well as protection of patient privacy and confidentiality. These policies developed in collaboration with pathology, surgery, the clinical protocol office and integrated with clinical and basic research policies allow a uniform, streamlined coordinated process of tissue procurement, handling, process, triage and analysis. The facility meets with each investigator to customize needs. The productivity and services provided by the TPA continues, as evidenced by numerous publications from user investigators and continued support of each of the SPORE projects and developmental studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-17
Application #
7904779
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
17
Fiscal Year
2009
Total Cost
$198,877
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
McRee, Autumn J; Marcom, Paul K; Moore, Dominic T et al. (2018) A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clin Breast Cancer 18:289-297
DeBono, Nathan L; Robinson, Whitney R; Lund, Jennifer L et al. (2018) Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. J Womens Health (Larchmt) 27:377-386
Nasarre, Patrick; Bonilla, Ingrid V; Metcalf, John S et al. (2018) TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanoma. Melanoma Res 28:185-194
Pearce, Oliver M T; Delaine-Smith, Robin M; Maniati, Eleni et al. (2018) Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. Cancer Discov 8:304-319
Williams, Lindsay A; Nichols, Hazel B; Hoadley, Katherine A et al. (2018) Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes Control 29:25-32
Couture, Heather D; Williams, Lindsay A; Geradts, Joseph et al. (2018) Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype. NPJ Breast Cancer 4:30
Lei, Jonathan T; Shao, Jieya; Zhang, Jin et al. (2018) Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 24:1434-1444.e7
Troester, Melissa A; Sun, Xuezheng; Allott, Emma H et al. (2018) Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110:
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12

Showing the most recent 10 out of 598 publications